Actively Recruiting
Randomized Study to Evaluate Safety, Tolerability, and Effects of Oral Emraclidine Compared to Placebo in Adults with Schizophrenia
Led by AbbVie · Updated on 2026-09-15
268
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Schizophrenia is a serious psychiatric condition that affects thinking, language, perception, and self-awareness. Researchers are studying an investigational oral drug called emraclidine in adults with schizophrenia to assess its safety, how it moves through the body, and its effect on disease activity. This phase 2 trial involves about 268 participants across multiple sites in the United States. Participants are divided into two parts Part A and Part B. In Part A, participants receive oral emraclidine or placebo for either 14 days or up to 21 days depending on the dosing schedule, which may include a titration period. In Part B, participants receive oral emraclidine or placebo for 42 days. Following treatment, all participants enter a 30-day safety follow-up period to monitor any adverse effects. During the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and side effect monitoring. Researchers also collect questionnaire data to evaluate changes in symptoms. The trial measures adverse events and detailed drug levels in the blood, along with clinical scales assessing symptom severity and improvement. Total participation lasts up to approximately 74 days, including treatment and follow-up.
CONDITIONS
Brief Title
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here